New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection
Psoriasis is a chronic immune‐mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life‐long treatment is needed to co...
Gespeichert in:
| Veröffentlicht in: | Dermatologic therapy 2021-01, Vol.34 (1), p.e14660-n/a |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 1 |
| container_start_page | e14660 |
| container_title | Dermatologic therapy |
| container_volume | 34 |
| creator | Ceccarelli, Manuela Venanzi Rullo, Emmanuele Berretta, Massimiliano Cacopardo, Bruno Pellicanò, Giovanni Francesco Nunnari, Giuseppe Guarneri, Claudio |
| description | Psoriasis is a chronic immune‐mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life‐long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL‐23/IL‐17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections. |
| doi_str_mv | 10.1111/dth.14660 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_dth_14660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DTH14660</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3600-2472f38da33461b9b1e4eb8a9e28ae4698447fa73ae9e95205539af7ff0449c93</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EolBY8APIWxZp7dhx4iUqjyJVsKCsIycZt4Y2rmxXVf-CT8ZpCjtmM68zd6SL0A0lIxpj3ITliHIhyAm6oFkqk4JQeRprJkVCUikG6NL7T0JoKhk9RwPGWKypuEDfr7DDC2jBqWBsiytjV3Zhao-1dTgsAQcHKqyhDdhqvPHWGeWNx6ptjl0wNVYuLJ0Jxo_we1ABOrY7jvMDWdvWm-b4JB5XdhsOgDP-q4NNq6HullfoTKuVh-tjHqKPp8f5ZJrM3p5fJvezpGaCkCTleapZ0SjGuKCVrChwqAolIS0UcCELznOtcqZAgsxSkmVMKp1rTTiXtWRDdNfr1s5670CXG2fWyu1LSsrO1TK6Wh5cjextz2621RqaP_LXxgiMe2BnVrD_X6l8mE97yR__eIPt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Ceccarelli, Manuela ; Venanzi Rullo, Emmanuele ; Berretta, Massimiliano ; Cacopardo, Bruno ; Pellicanò, Giovanni Francesco ; Nunnari, Giuseppe ; Guarneri, Claudio</creator><creatorcontrib>Ceccarelli, Manuela ; Venanzi Rullo, Emmanuele ; Berretta, Massimiliano ; Cacopardo, Bruno ; Pellicanò, Giovanni Francesco ; Nunnari, Giuseppe ; Guarneri, Claudio</creatorcontrib><description>Psoriasis is a chronic immune‐mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life‐long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL‐23/IL‐17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.</description><identifier>ISSN: 1396-0296</identifier><identifier>EISSN: 1529-8019</identifier><identifier>DOI: 10.1111/dth.14660</identifier><identifier>PMID: 33301216</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Arthritis, Psoriatic - diagnosis ; Arthritis, Psoriatic - drug therapy ; Biological Products - adverse effects ; Biological Products - therapeutic use ; Humans ; infection ; Inflammation ; interleukin‐17 ; interleukin‐23 ; psoriasis ; Psoriasis - diagnosis ; Psoriasis - drug therapy ; psoriatic arthritis ; SARS‐CoV‐2 ; Skin</subject><ispartof>Dermatologic therapy, 2021-01, Vol.34 (1), p.e14660-n/a</ispartof><rights>2020 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3600-2472f38da33461b9b1e4eb8a9e28ae4698447fa73ae9e95205539af7ff0449c93</citedby><cites>FETCH-LOGICAL-c3600-2472f38da33461b9b1e4eb8a9e28ae4698447fa73ae9e95205539af7ff0449c93</cites><orcidid>0000-0001-5987-3576 ; 0000-0002-7465-0714 ; 0000-0002-9837-9148 ; 0000-0001-8273-5382 ; 0000-0003-3918-8779 ; 0000-0002-8113-8452 ; 0000-0002-9640-8742</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdth.14660$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdth.14660$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33301216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ceccarelli, Manuela</creatorcontrib><creatorcontrib>Venanzi Rullo, Emmanuele</creatorcontrib><creatorcontrib>Berretta, Massimiliano</creatorcontrib><creatorcontrib>Cacopardo, Bruno</creatorcontrib><creatorcontrib>Pellicanò, Giovanni Francesco</creatorcontrib><creatorcontrib>Nunnari, Giuseppe</creatorcontrib><creatorcontrib>Guarneri, Claudio</creatorcontrib><title>New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection</title><title>Dermatologic therapy</title><addtitle>Dermatol Ther</addtitle><description>Psoriasis is a chronic immune‐mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life‐long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL‐23/IL‐17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.</description><subject>Arthritis, Psoriatic - diagnosis</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Biological Products - adverse effects</subject><subject>Biological Products - therapeutic use</subject><subject>Humans</subject><subject>infection</subject><subject>Inflammation</subject><subject>interleukin‐17</subject><subject>interleukin‐23</subject><subject>psoriasis</subject><subject>Psoriasis - diagnosis</subject><subject>Psoriasis - drug therapy</subject><subject>psoriatic arthritis</subject><subject>SARS‐CoV‐2</subject><subject>Skin</subject><issn>1396-0296</issn><issn>1529-8019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EolBY8APIWxZp7dhx4iUqjyJVsKCsIycZt4Y2rmxXVf-CT8ZpCjtmM68zd6SL0A0lIxpj3ITliHIhyAm6oFkqk4JQeRprJkVCUikG6NL7T0JoKhk9RwPGWKypuEDfr7DDC2jBqWBsiytjV3Zhao-1dTgsAQcHKqyhDdhqvPHWGeWNx6ptjl0wNVYuLJ0Jxo_we1ABOrY7jvMDWdvWm-b4JB5XdhsOgDP-q4NNq6HullfoTKuVh-tjHqKPp8f5ZJrM3p5fJvezpGaCkCTleapZ0SjGuKCVrChwqAolIS0UcCELznOtcqZAgsxSkmVMKp1rTTiXtWRDdNfr1s5670CXG2fWyu1LSsrO1TK6Wh5cjextz2621RqaP_LXxgiMe2BnVrD_X6l8mE97yR__eIPt</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Ceccarelli, Manuela</creator><creator>Venanzi Rullo, Emmanuele</creator><creator>Berretta, Massimiliano</creator><creator>Cacopardo, Bruno</creator><creator>Pellicanò, Giovanni Francesco</creator><creator>Nunnari, Giuseppe</creator><creator>Guarneri, Claudio</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-5987-3576</orcidid><orcidid>https://orcid.org/0000-0002-7465-0714</orcidid><orcidid>https://orcid.org/0000-0002-9837-9148</orcidid><orcidid>https://orcid.org/0000-0001-8273-5382</orcidid><orcidid>https://orcid.org/0000-0003-3918-8779</orcidid><orcidid>https://orcid.org/0000-0002-8113-8452</orcidid><orcidid>https://orcid.org/0000-0002-9640-8742</orcidid></search><sort><creationdate>202101</creationdate><title>New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection</title><author>Ceccarelli, Manuela ; Venanzi Rullo, Emmanuele ; Berretta, Massimiliano ; Cacopardo, Bruno ; Pellicanò, Giovanni Francesco ; Nunnari, Giuseppe ; Guarneri, Claudio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3600-2472f38da33461b9b1e4eb8a9e28ae4698447fa73ae9e95205539af7ff0449c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Arthritis, Psoriatic - diagnosis</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Biological Products - adverse effects</topic><topic>Biological Products - therapeutic use</topic><topic>Humans</topic><topic>infection</topic><topic>Inflammation</topic><topic>interleukin‐17</topic><topic>interleukin‐23</topic><topic>psoriasis</topic><topic>Psoriasis - diagnosis</topic><topic>Psoriasis - drug therapy</topic><topic>psoriatic arthritis</topic><topic>SARS‐CoV‐2</topic><topic>Skin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ceccarelli, Manuela</creatorcontrib><creatorcontrib>Venanzi Rullo, Emmanuele</creatorcontrib><creatorcontrib>Berretta, Massimiliano</creatorcontrib><creatorcontrib>Cacopardo, Bruno</creatorcontrib><creatorcontrib>Pellicanò, Giovanni Francesco</creatorcontrib><creatorcontrib>Nunnari, Giuseppe</creatorcontrib><creatorcontrib>Guarneri, Claudio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Dermatologic therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ceccarelli, Manuela</au><au>Venanzi Rullo, Emmanuele</au><au>Berretta, Massimiliano</au><au>Cacopardo, Bruno</au><au>Pellicanò, Giovanni Francesco</au><au>Nunnari, Giuseppe</au><au>Guarneri, Claudio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection</atitle><jtitle>Dermatologic therapy</jtitle><addtitle>Dermatol Ther</addtitle><date>2021-01</date><risdate>2021</risdate><volume>34</volume><issue>1</issue><spage>e14660</spage><epage>n/a</epage><pages>e14660-n/a</pages><issn>1396-0296</issn><eissn>1529-8019</eissn><abstract>Psoriasis is a chronic immune‐mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life‐long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL‐23/IL‐17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>33301216</pmid><doi>10.1111/dth.14660</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5987-3576</orcidid><orcidid>https://orcid.org/0000-0002-7465-0714</orcidid><orcidid>https://orcid.org/0000-0002-9837-9148</orcidid><orcidid>https://orcid.org/0000-0001-8273-5382</orcidid><orcidid>https://orcid.org/0000-0003-3918-8779</orcidid><orcidid>https://orcid.org/0000-0002-8113-8452</orcidid><orcidid>https://orcid.org/0000-0002-9640-8742</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1396-0296 |
| ispartof | Dermatologic therapy, 2021-01, Vol.34 (1), p.e14660-n/a |
| issn | 1396-0296 1529-8019 |
| language | eng |
| recordid | cdi_crossref_primary_10_1111_dth_14660 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Arthritis, Psoriatic - diagnosis Arthritis, Psoriatic - drug therapy Biological Products - adverse effects Biological Products - therapeutic use Humans infection Inflammation interleukin‐17 interleukin‐23 psoriasis Psoriasis - diagnosis Psoriasis - drug therapy psoriatic arthritis SARS‐CoV‐2 Skin |
| title | New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A21%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20generation%20biologics%20for%20the%20treatment%20of%20psoriasis%20and%20psoriatic%20arthritis.%20State%20of%20the%20art%20and%20considerations%20about%20the%20risk%20of%20infection&rft.jtitle=Dermatologic%20therapy&rft.au=Ceccarelli,%20Manuela&rft.date=2021-01&rft.volume=34&rft.issue=1&rft.spage=e14660&rft.epage=n/a&rft.pages=e14660-n/a&rft.issn=1396-0296&rft.eissn=1529-8019&rft_id=info:doi/10.1111/dth.14660&rft_dat=%3Cwiley_cross%3EDTH14660%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33301216&rfr_iscdi=true |